CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
about
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesDifferential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.The history and future of targeting cyclin-dependent kinases in cancer therapy.The Role of CDK4/6 Inhibition in Breast Cancer.Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment responseOvercoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 InhibitorsPD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.CDK4/6 inhibition is more active against the glioblastoma proneural subtype.ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells.Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.Cell Cycle Regulation in Treatment of Breast Cancer.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Transcription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancer.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence.Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugsCDK4/6 inhibition in breast cancer: current practice and future directions
P2860
Q28072897-F6FC95BE-66F8-42D0-A25D-8C66C981C6BDQ33709284-9B35A0B3-5492-4C0A-9EE5-5B17E8523C29Q34460347-45C43DD0-1EA5-4EE0-B041-F54C9B499DD3Q35586728-00D01AA8-93F5-4D65-BD45-6D14CAD14515Q36140625-88E11453-5EA8-43CA-BE8F-02DE2469828DQ36207381-D0869FD9-2C53-4C43-B73A-42159A8B88D2Q36420373-8AF84303-09FF-4A33-BE5A-B0FD46533FB0Q37709050-E5D10178-B51B-46D8-A1F1-5A1A944C2C2BQ38663540-BD0F6640-8C6A-4787-B352-CB4EBF0028A9Q39183079-A8444805-77E0-40FD-9ED7-039E8472C4FEQ39433738-FDB92CEF-1F26-430A-A297-74D8DE9E18C8Q41548769-2B85C19F-AF1F-44C5-9A4B-87A6C0032F09Q47350657-28A59A6D-0655-48C5-BB16-F9BFF6D70EB3Q48125385-B42C0616-C110-4507-818D-29A51C3B2BE3Q49335307-D79F684F-70E5-4F11-9DC7-B4DCE308971DQ49544319-22F31EE8-88C5-4361-B304-36A27677CB42Q49544395-39BC7CD4-B80D-4B34-9BA0-817DBD5C7E0CQ49732981-884FD80C-F7F7-481E-8D08-8A198F95EE94Q52578959-09630866-352C-44E1-9D93-962F0D4ABDA7Q54969586-D6CF217E-F185-4955-84CC-01DA34770179Q55710176-960E99C8-434A-455D-BF1F-B23DE9F151AEQ57106864-8320F218-BAC4-43CE-9443-7A648B3D7C74Q57109486-1A084F59-A6DE-49C7-BD58-6A9676CE44E7
P2860
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CDK4/6 inhibition provides a p ...... clinical breast cancer models.
@en
CDK4/6 inhibition provides a p ...... clinical breast cancer models.
@nl
type
label
CDK4/6 inhibition provides a p ...... clinical breast cancer models.
@en
CDK4/6 inhibition provides a p ...... clinical breast cancer models.
@nl
prefLabel
CDK4/6 inhibition provides a p ...... clinical breast cancer models.
@en
CDK4/6 inhibition provides a p ...... clinical breast cancer models.
@nl
P2093
P2860
P1433
P1476
CDK4/6 inhibition provides a p ...... clinical breast cancer models.
@en
P2093
Agnieszka K Witkiewicz
Erik S Knudsen
P2860
P304
P356
10.18632/GENESANDCANCER.24
P577
2014-07-01T00:00:00Z